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Direct to consumer genetic testing offered via the Internet has been available for
over a decade. Initially most tests of this type were offered without the input of the
consumer’s own health professional. Ethical and practical concerns have been a
raised over the use of such tests: these include fulfilling the requirement for
informed consent, utility of results for health care management and the potential
burden placed upon health services by people who have taken tests.
These tests now have an application in reproductive healthcare. The advent of
non-invasive prenatal testing has facilitated the genetic testing of the fetus using
only a maternal blood sample. However, companies offering such tests, for example
for aneuploidy, appear to be doing so based on a referral from the mother’s health
professional. Preconception or prenatal carrier testing for a range of autosomal
recessive conditions can be purchased without the input of a health professional
who knows the prospective parents. However, unless the appropriate mutations for
the specific population are included in the test, results may create false reassurance.
Paternity testing without the consent of the putative father is also available via the
Internet, as are tests to ascertain the sex of the fetus, which may be used to select
children of a specific gender.
Direct-to-consumer tests may support prospective parents to identify genetic risk to
their future children, however, it is important that they are aware of the possible
limitations, as well as advantages, of these tests. National regulation may not prove
effective in ensuring the safety of all individuals involved, therefore international
pressure to ensure companies conform to Codes of Practice may be needed,
especially in relation to tests that could influence reproductive decisions. However,
health professionals have a duty to ensure they are sufficiently knowledgeable to
enable them to guide patients appropriately.
Keywords: Direct-to-consumer; Non-invasive prenatal test; Reproduction; Genetic
test; EthicsIntroduction
For over a decade, it has been possible for individuals to purchase genetic and/or gen-
omic tests over the Internet: these are termed direct-to-consumer (DTC) tests (Borry
et al. 2010). In a commercial transaction, the consumer pays the company directly and
it is possible to obtain tests without the involvement of a health professional (Eng and
Sharp 2010), although increasingly companies are offering health professional contact2015 Skirton; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution
icense (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
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consumer’s doctor or health professional (Borry et al. 2010). Because of the shift in ap-
proach to include health professional input, the term ‘direct to consumer’ now de-
scribes a range of tests that are more directly accessible to consumers than those
offered via the existing health services, with or without the involvement of a health pro-
fessional. In the pharmacogenomics context, the term ‘beyond-the–clinic’ (BTC) has
been suggested as an alternative to DTC (Prainsack and Vayena, 2013), however as this
term is not yet generally employed, in this paper ‘DTC’ will be used.
Many DTC companies offer a panel of genetic or genomic tests that are purchased
en bloc by the consumer, making consent procedures a challenge (Bunnik et al. 2012).
The combination of different tests varies according to the company, but the panel fre-
quently comprises tests for gene mutations for monogenic disorders, carrier tests for
autosomal recessive conditions, tests for gene variants that could indicate susceptibility
to a number of common diseases (Cornel et al. 2014), pharmacogenomic tests (Chua
and Kennedy 2012) and sometimes tests that indicate specific physical characteristics,
such as ear lobe thickness (Samuel et al. 2010). Of these, the tests that are of most rele-
vance in the reproductive context are carrier tests that may identify the potential risk
of any offspring having an autosomal recessive condition.
There have been significant ethical concerns raised over the marketing and use of
DTC tests (Caulfield and McGuire 2012). Marketing is often based on enhancement of
personal empowerment, with claims that use of the tests will enable individuals to have
more control over their own health (Annas and Elias 2014). However, these claims have
recently been brought into the spotlight with the warning to 23andme™ (23andme
2014) by the FDA that they could not substantiate the claims they made about the tests
they offered (Annas and Elias 2014). It is possibly not surprising that three of the best
known DTC companies, 23andme™, DeCODEme™ (deCODEme 2014) and Navigenics
(Navigenics 2014) are not at present offering DTC testing for susceptibility to common
diseases, but some continue to offer tests related to pregnancy, such as gender and
paternity testing.
A series of three systematic reviews on DTC genetic and genomic testing in prepar-
ation for the development of a decision tool to support health professionals to advise
patients considering a DTC test (Jackson et al. 2014): this is described later in the
paper. When undertaking the review on service users’ views (Goldsmith et al. 2013), we
found that there was a paucity of evidence on this topic and those studies that have
been undertaken chiefly reported views of individuals with a professional interest in
genetics or those who had been offered tests free or at a reduced price. In addition,
many of the studies on user motivation involved potential, rather than actual, users of
DTC tests. The available evidence on motivations for purchasing a DTC test indicated
that users wish to obtain information about their own genetic makeup due to curiosity,
to have more detail about risks for specific conditions (such as heart disease) or to help
them manage their own health, for example through informing lifestyle choices. Inter-
estingly, informing reproductive choice was not perceived as a motivating factor for use
of DTC tests. While users were generally enthusiastic about the tests, there was little
evidence that the results did help them to manage their health more effectively. How-
ever, it may be significant that in a study of 3640 individuals who were asked about
their attitudes towards having a DTC personalised genetic risk assessment, those
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others in the sample (Bloss et al. 2010).
In a review of health professional attitudes towards and experiences of DTC (Goldsmith
et al. 2013), health professionals appeared wary about the use of DTC tests, although
many of those studied had no experience of working with patients who had used them.
Those working in the United States were more likely to support access to DTC than those
outside that country. This may be related to perceptions of access to healthcare, as some
health professionals felt that having direct access to genetic testing could reduce some of
the inequities of health services, although it is difficult to see how those patients who do
not have good access to clinical care could afford and/or benefit from DTC testing.
In a third review of existing policies on DTC testing, the published views of profes-
sional organisations and bioethics committees were synthesised (Skirton et al. 2012).
The majority of organisations urged caution over the use of such tests, citing a lack of
demonstrable benefit for consumers, risks of false reassurance or unwarranted anxiety
and additional strain on the existing health services as negative outcomes of tests. Pro-
fessional organisations and bioethics committees have highlighted the necessity of in-
formation (Table 1) and counselling to accompany DTC testing, emphasising that this
should be available both pre and post-test (Skirton et al. 2012). However, this may not
be perceived as important by consumers. In a study of consumer uptake of counselling
services to accompany DTC testing, Darst et al. (2013) found that only 14.1% of their
1325 respondents had used the counselling services offered by the company. Many of
those who did not utilise this option felt they already understood their results, however,
the authors were unable to assess whether this was actually so and if DTC results were
used as a basis for reproductive decisions , correct understanding of the results would
be crucial.
While it may not be appropriate to align DTC tests with the same standards that
would be required to obtain informed consent in a clinical context, some key issues
should be understood by patients to reduce the chance of harm. The first is that al-
though some mutations for single gene disorders may be included in the test, the com-
pany may not include all potential mutations (Cornel et al. 2014), or even those thatTable 1 Information required by consumers to make an informed decision about DTC
testing (H. Skirton et al., 2012)
Information related
to genetic condition
Information related to test Security issues
General information
about genetics
Purpose and nature of the test(s) Confidentiality of
results
Availability of treatment or
lack of treatment
Risks associated with testing Management and care
of the sample
Implications of the result Clinical utility of tests Subsequent use or
storage of sample









Format and presentation of
results
Sources of independent information
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could result in prospective parents being falsely reassured that they do not carry a re-
cessive condition that could affect their future children. The second point is that the
tests for susceptibility to common disorders may be based on studies that indicate only
weak associations between the genomic variant and the condition (Moonesinghe et al.
2011), or may include conditions with low heritability (Janssens and van Duijn 2010).
Thus, the power of such tests to predict the likelihood of the individual developing one
of the common diseases is often uncertain. These factors all indicate a need for regula-
tion of DTC testing and this is consistent with the views of health professionals
(Goldsmith et al. 2013). However consumers demonstrate a degree of ambiguity around
regulation: Bollinger et al. (2013) discovered that while consumers wanted regulation
and government oversight of DTC companies, they also wanted unrestrained access to
DTC testing.
DTC in reproductive contexts
While DTC tests are offered and used in a range of contexts, some individuals or cou-
ples may wish to use them to support reproductive choice and decision making. Here I
will discuss their potential use during the preconception and/or prenatal periods.
Prenatal testing using DTC and NIPT
The advent of fetal testing using cell-free fetal DNA in maternal serum has created
feasible options for DTC prenatal testing (Hill et al. 2012a). Prior to the develop-
ment of techniques to analyse fetal material in maternal circulation, invasive
methods to extract fetal material for testing were required, necessitating the in-
volvement of the mother’s personal health professional to take a sample (Skirton
and Patch 2013). de Jong et al. (2010) raised alarms about the potential societal
impact of the use of DTC tests in this application. However, the recommendations
by European Academies Science Advisory Council (EASAC) and Federation of
European Academies of Medicine (FEAM) (2012) specifically exclude the use of
DTC for prenatal testing for health-related purposes, stating that the implications
of the result and consequences of the test are so profound that it would not be ap-
propriate to provide prenatal diagnosis without the input of relevant health profes-
sionals to provide quality care (Section 4.1.2, p17,18). Perhaps partly due to these
recommendations, DTC companies offering tests such as Harmony™ (Ariosa 2014),
Panorama™ (Panorama 2014), Verifi® (Illumina 2014) and MaterniT21™ (Sequenom
2014) do not at present appear to be offering NIPT in Europe as a direct-to-
consumer test without a health professional referral. Thus, NIPT tests can be or-
dered, to detect aneuploidy such as Down syndrome in the fetus for example, but
only via the mother’s health professional. However, the marketing emphasis is on
reassurance for the parents, rather than the chance of detecting the condition. For
example, the Panorama™ website (Panorama 2014) states ‘The Panorama prenatal
test: because you deserve the reassurance that comes from having the most accur-
ate and comprehensive genetic information available’. The onus is on the mother’s
health professional to ensure she is aware that, beside the chance that the test re-
sult will reassure her, there is also the chance that the result may show the fetus is
affected.
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One application of DTC testing that could be of genuine use to consumers is the
option of carrier testing for autosomal recessive conditions such as cystic fibrosis,
thalassaemia and spinal muscular atrophy. These conditions are individually rare
and the chance of having a child with another carrier of the same condition is low,
unless the parents are biologically related (Ten Kate et al. 2010). This means that
unless an affected child is born into the family, carriers are generally unaware of
their status. It is generally preferable that carrier testing to determine the genetic
carrier status of the parents is undertaken prior to pregnancy to allow the couple
more reproductive options and more time to make decisions, however, carrier test-
ing is also possible during the pregnancy. This section relates to parental carrier
testing in both scenarios.
In section 4.1.3 of the EASAC/FEAM recommendations (European Academies Sci-
ence Advisory Council and Federation of European Academies of Medicine 2012) it is
stated that genetic counselling is an essential component of preconception carrier test-
ing to enable the individual to understand the risks to themselves and their families.
The report further states that the ability of DTC companies to provide the requisite
counselling is suspect, therefore it is highly preferable that it is carried out within the
public health service sector and DTC companies should actually advise potential cus-
tomers of this recommendation.
There are substantial differences in the products provided by companies offering car-
rier testing. At the time of writing, ‘Counsyl’ (Counsyl 2014), based in the Netherlands,
offered tests for 100 conditions for $599 (US), while ‘Gentle’ (Gentle, 2014) provided
testing for 1700 conditions for $1990. With regard to pre and post test counselling, in-
formation on the Counsyl website states that counselling is complimentary, but the na-
ture of that counselling is not clear. Gentle uses a service called ‘Royal Doctors’ (Royal
Doctors 2014) to provide telephone counselling to patients.
While carrier testing for a range of recessive conditions offers the chance to de-
termine the genetic risk (if one exists) to future children, as previously stated, it is
important that the test cover those mutations of relevance to the population
(Cornel et al. 2014). The consumer therefore needs to ensure that the mutations
relevant to his or her ethnicity are tested. In addition, any results that could be
acted upon (for example if prenatal diagnosis is planned) should be obtained from
an accredited laboratory using health service standards (European Academies Sci-
ence Advisory Council and Federation of European Academies of Medicine 2012).
The reproductive health services offered in the consumer’s country could also be
relevant to the consumer’s decision to purchase a DTC preconception or prenatal
test. For example, prenatal diagnosis, preimplantation diagnosis and/or termination
of pregnancy for fetal abnormality may or may not be available to the couple. The
options for pregnancy management may influence their request for carrier testing
and individuals who are made aware, for example, that termination of pregnancy
would not be possible may decide against testing on the grounds that it may in-
crease their anxiety without offering them a chance to influence the outcome of the
pregnancy.
In choosing DTC carrier screening, consumers should also be informed that the
panel of tests may include tests for mutations that cause adult-onset disorders, such as
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relevance to their own and their biological relatives’ future health.
Paternity testing and gender identification
While DTC companies are not currently offering prenatal testing for genetic conditions
in Europe, a number are offering tests for paternity and identification of fetal sex, often
called gender testing, using NIPT. In the United Kingdom, paternity testing is regulated
under the Human Tissue Act (2004) and it is illegal to undertake it without the father’s
informed consent, due to the many psychological, social and legal implications of the
results. The use of maternal serum (containing maternal and fetal DNA) in combin-
ation with DNA obtained from the potential father would enable paternity testing to be
undertaken during pregnancy without invasive testing and without the knowledge of
the father.
These developments were predicted as early as 2009 in a report for the Public Health
Genetics Foundation, where the authors (Wright and Burton 2009) alerted readers to
the improbability of being able to ensure that paternity testing was only undertaken
with the full consent of the putative father(s). In the same report, it was suggested that
a Code of Conduct be established to protect individuals who might be involved in
NIPT testing. However, a number of DTC companies are offering NIPT paternity test-
ing and some openly advertise the option for the mother to maintain complete confi-
dentiality and to send material from the father from which DNA can be extracted
without his knowledge. In one example, the Prenatal Genetics Center (2014) state that
for a cost of $990 they offer:
‘Full confidentiality of our testing: the mother can submit different samples from the
alleged father(s) without asking him. Our laboratory is accepting hair samples, tooth-
brushes, semen stain and other forensic samples collected from the alleged father.’.
Under the heading ‘Counseling’ on the same website, the company offers advice on the
best types of paternal sample and optimal times to obtain samples, however the impli-
cations of the test results are not addressed.
The option of obtaining a paternity test result without the father’s consent could be
seen to have some benefits for the mother, as she would be able to conceal any doubts
about the paternity of her child that could disrupt her relationship with her partner.
However, from the father’s perspective there could be both moral and legal objections,
as having his genetic material tested without his knowledge could be seen as a violation
of his human rights and could result in his alienation from a child he believes is his,
without full explanation.
In other pregnancy related applications of DTC testing, some companies offer gender
identification for the fetus, however feedback by consumers on the performance of some of
them has been less than complimentary. For example, for one test offered by Gendermaker
was marketing their test) via Amazon (Amazon.co.uk 2014a), but customer feedback indi-
cated that many parents were unhappy with the reliability of the test (Amazon.co.uk
2014b) and what they felt was misrepresentation regarding the costs. There is a serious
concern about the use of gender testing to identify and terminate a fetus that is not of the
desired sex. In countries where it is illegal to perform an abortion based purely on the sex
of the fetus, it is possible that parents could have a DTC test without the knowledge of a
health professional and present with a request for abortion on other social grounds.
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It appears that the situation that would be most concerning from a counselling perspec-
tive, where prenatal tests for genetic conditions were offered without health professional
input, is not currently a threat. Those companies offering NIPT for genetic conditions are
doing so via a referral from the mother’s own health professional and this puts the onus
for counselling for the test on that health professional, to comply with international
recommendations (European Academies Science Advisory Council and Federation of
European Academies of Medicine 2012). It also means that health professionals can exert
consumer power if the tests are not of an acceptable standard and decline to use the com-
pany, but this does require them to make the appropriate investigations about suitability,
specificity and sensitivity of each test before recommending the DTC company is used.
They should also ensure that laboratories used by DTC companies are assessed as part of
recognised quality assurance schemes (European Academies Science Advisory Council
and Federation of European Academies of Medicine 2012).
Those companies offering tests for paternity or gender are still operating, but very
susceptible to public review. The potential breach of law through offering paternity
testing without the father’s consent is a problematic legal issue, but I would argue that
it is not one that can or should be addressed via health services for two main reasons.
First, paternity is not essentially a health issue and second, the nature of private pater-
nity testing means it would be undertaken independently of health professional know-
ledge. Testing for fetal sex can be used to inform the status of a fetus at risk of a sex-
linked disorder (Hill et al. 2012b), but this type of testing would be performed under
the auspices of the health service. Testing for fetal sex purely for parental information
is not the concern of health professionals, however the potential for termination of a
fetus of a particular sex for social reasons raises ethical and legal concerns. Termination
of pregnancy is a process that would involve health professionals and they therefore
need to be aware of the existence of DTC gender testing outside the health service.
This knowledge in itself should motivate health professionals to consider the possibility
that prior knowledge of the fetal sex may motivate a request for termination and
prompt them to explore the reasons for such a request.
Regarding use of DTC tests to assess carrier status, it is important for health profes-
sional and policy makers to be aware of the current situation with respect to DTC tests
and to respond accordingly. This involves having the knowledge to guide or advise pa-
tients regarding the use of such tests. For this purpose, a decision tool (Skirton et al.
2014) was developed through consensus of an expert group to support health profes-
sionals in discussions with patients who might be considering a DTC test. It is sug-
gested that health professionals who are faced with a patient asking for advice about
taking a DTC test ask the patient ‘Why do you wish to have a DTC test?’. The decision
tool was organised to provide information on the utility of using a DTC test in seven
potential patient scenarios, based on the patient’s response to that question. With re-
spect to reproductive issues, it is possible that prospective parents may be concerned
about an existing genetic condition in the family or be members of an ethnic group
with an increased risk of a specific disorder, in which case genetic testing through the
health service would be advised rather than DTC testing. For those who are more gen-
erally concerned to reduce any risks to their potential offspring and wish to be tested
for carrier status a wide range of autosomal recessive conditions, DTC testing may be a
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2014) and can be accessed by both health professionals and by patients seeking
information.Conclusion
Direct-to-consumer tests may support prospective parents to identify genetic risk to
their future children, however, it is important that they are aware of the possible limita-
tions, as well as advantages, of these tests. For tests offered via the Internet, national
regulation may not prove effective in ensuring the safety of all individuals involved,
therefore international pressure to ensure companies conform to Codes of Practice
may be needed, especially in relation to tests that could influence reproductive deci-
sions. However, health professionals have a duty to ensure they are sufficiently
knowledgeable to enable them to guide or advise patients appropriately.
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